Changes in molecular targets and defective signaling pathways are altering the sensitivity of tumor cells to anticancer drugs. For example, the mechanism of action of anthracyclines is based on their ability to interact with DNA topoisomerases. Mutations in the TOP1 gene, encoding topoisomerase 1 led to a reduced ability of anthracyclines to interact with their target. This evidence concerns the gene TOP1 and neoplasm.